Breathe Vision 2030

Lung patients and health care professionals together for better prevention, care and patient participation on respiratory health.

The Breathe Vision is a collective initiative driven by European level patient groups and healthcare professionals that have come together in a European Lung Health Group.

We are an informal group of 9 European level patients and healthcare professionals' organisations gathering 179 member associations across 34 European countries, including 9 from non-EU states.

Our mission centres around bringing together know-how to support our organisations in empowering patients with lung diseases, improving early diagnosis, optimising multidisciplinary care, progressing quality of life, and research. At the European level, we reinforce the messages of our organisations to strive for better care, increased patient participation and improved prevention.

The Breathe Vision has been initiated by the following organisations:

Alpha-1 Plus Belgium

Cystic Fibrosis Europe (CF-E)

European Federation of Allergy and Airways Diseases Patients’ Associations (EFA)

European Lung Foundation (ELF)

European Pulmonary Fibrosis Federation (EU-PFF)

European Respiratory Society (ERS)

Lung Cancer Europe (LuCE)

Pulmonary Hypertension Association Europe (PHA-E)

Tuberculosis Coalition Europe (TBEC)

We bring together patient groups and societies of health care professionals advocating together for better prevention, care and patient participation in respiratory health.

Our Breathe Vision for 2030 brings together the visions and priorities of all these stakeholders and aims at increasing awareness and prevention for respiratory health by 2030, improving lung health care and research, and tackling COVID-19 and its long-term impacts in Europe.

For instance, there have been no new classes of respiratory disease in 50 years. We continue to use and are guided by broad terms like asthma and chronic obstructive pulmonary disease (COPD) which still have no essential curative treatments, something that is also largely missing or not widely accessible for rare lung diseases.

Breathe Vision for 2030 seeks to influence European and EU policy priorities to maximise their benefits for respiratory health. As we stand firm together to convey this Vision, we promote increased awareness and understanding of respiratory diseases in society.

Together and individually, we engage with European level stakeholders to encourage them to recognise respiratory health as a public health priority and to take action to improve the quality of life of lung disease patients. A key mechanism of doing this is through the MEP Lung Health Group.

EFA thanks its sustainable funding partners for their unrestricted educational grants which have helped the association in coordinating the work towards the Breathe Vision for 2030 and activities:

2023: Astra Zeneca, Chiesi and Roche
2022: AstraZeneca, Boehringer Ingelheim, Chiesi, and Roche
2021: AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Roche
2020: AbbVie, Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK and Sanofi-Regeneron